JP2013512252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512252A5 JP2013512252A5 JP2012541183A JP2012541183A JP2013512252A5 JP 2013512252 A5 JP2013512252 A5 JP 2013512252A5 JP 2012541183 A JP2012541183 A JP 2012541183A JP 2012541183 A JP2012541183 A JP 2012541183A JP 2013512252 A5 JP2013512252 A5 JP 2013512252A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- compound
- salt
- therapeutic agent
- hemi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 239000003814 drug Substances 0.000 claims 41
- 229940124597 therapeutic agent Drugs 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000945 filler Substances 0.000 claims 15
- 101150053185 P450 gene Proteins 0.000 claims 12
- 229940095064 tartrate Drugs 0.000 claims 12
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 9
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 239000007787 solid Substances 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 8
- 239000013078 crystal Substances 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 6
- 239000000314 lubricant Substances 0.000 claims 6
- 230000004060 metabolic process Effects 0.000 claims 6
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 5
- 208000024720 Fabry Disease Diseases 0.000 claims 5
- 208000015872 Gaucher disease Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 238000012360 testing method Methods 0.000 claims 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 4
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 4
- 229920000881 Modified starch Polymers 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229940049654 glyceryl behenate Drugs 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 230000002503 metabolic effect Effects 0.000 claims 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 4
- 239000008107 starch Substances 0.000 claims 4
- 235000019698 starch Nutrition 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 241000209149 Zea Species 0.000 claims 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229960004977 anhydrous lactose Drugs 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 235000011010 calcium phosphates Nutrition 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 2
- -1 copolyvidone Polymers 0.000 claims 2
- 235000005822 corn Nutrition 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- 229960004125 ketoconazole Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229960001404 quinidine Drugs 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229960002668 sodium chloride Drugs 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 claims 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 244000043261 Hevea brasiliensis Species 0.000 claims 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical group OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 150000002339 glycosphingolipids Chemical class 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 229960002127 imiglucerase Drugs 0.000 claims 1
- 108010039650 imiglucerase Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical group CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 claims 1
- 229960001512 miglustat Drugs 0.000 claims 1
- 229920003052 natural elastomer Polymers 0.000 claims 1
- 229920001206 natural gum Polymers 0.000 claims 1
- 229920001194 natural rubber Polymers 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- FJZZPCZKBUKGGU-AUSIDOKSSA-N CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](c1ccc2OCCOc2c1)O)=O Chemical compound CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](c1ccc2OCCOc2c1)O)=O FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 | |
| US61/264,748 | 2009-11-27 | ||
| PCT/US2010/057952 WO2011066352A1 (en) | 2009-11-27 | 2010-11-24 | An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134942A Division JP6370264B2 (ja) | 2009-11-27 | 2015-07-06 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2016041843A Division JP6452635B2 (ja) | 2009-11-27 | 2016-03-04 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512252A JP2013512252A (ja) | 2013-04-11 |
| JP2013512252A5 true JP2013512252A5 (enExample) | 2014-01-16 |
Family
ID=43431870
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541183A Pending JP2013512252A (ja) | 2009-11-27 | 2010-11-24 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2015134942A Active JP6370264B2 (ja) | 2009-11-27 | 2015-07-06 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2016041843A Active JP6452635B2 (ja) | 2009-11-27 | 2016-03-04 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2018167432A Active JP7150528B2 (ja) | 2009-11-27 | 2018-09-07 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2020136889A Pending JP2020189873A (ja) | 2009-11-27 | 2020-08-14 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2023101301A Pending JP2023116764A (ja) | 2009-11-27 | 2023-06-21 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134942A Active JP6370264B2 (ja) | 2009-11-27 | 2015-07-06 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2016041843A Active JP6452635B2 (ja) | 2009-11-27 | 2016-03-04 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2018167432A Active JP7150528B2 (ja) | 2009-11-27 | 2018-09-07 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2020136889A Pending JP2020189873A (ja) | 2009-11-27 | 2020-08-14 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
| JP2023101301A Pending JP2023116764A (ja) | 2009-11-27 | 2023-06-21 | グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩 |
Country Status (40)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| MY160542A (en) | 2009-11-27 | 2017-03-15 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| EP2721151B1 (en) * | 2011-06-20 | 2017-12-06 | Mount Sinai School Of Medicine | Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders |
| US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| LT2854910T (lt) | 2012-06-01 | 2020-05-25 | Icahn School Of Medicine At Mount Sinai | Ceramido lygiai infekcijos gydymo ir prevencijos metu |
| HRP20191361T1 (hr) | 2013-03-14 | 2019-11-01 | Icahn School Med Mount Sinai | Pripravci ceramidaze terapeutske kiseline i postupci njihove izrade i uporabe |
| EP3912977A1 (en) * | 2013-09-20 | 2021-11-24 | BioMarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| US20170129869A1 (en) * | 2014-07-03 | 2017-05-11 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| ES2716420T3 (es) | 2015-04-14 | 2019-06-12 | Sandoz Ag | Clorhidrato de eliglustat cristalino |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| MX2018006250A (es) | 2015-11-18 | 2018-09-05 | Genzyme Corp | Biomarcador de enfermedad poliquistica renal y usos del mismo. |
| CN109071526B (zh) | 2016-02-25 | 2023-02-28 | 阿森纽荣股份公司 | 哌嗪衍生物的酸加成盐 |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| WO2018225085A1 (en) | 2017-06-05 | 2018-12-13 | Cipla Limited | Stable solid dispersions of eliglustat hemitartrate |
| AU2018283289B2 (en) * | 2017-06-16 | 2021-03-25 | Beta Pharma, Inc. | Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| EP3664798B1 (en) | 2017-08-08 | 2025-10-29 | Amneal Pharmaceuticals LLC | Pharmaceutical composition comprising eliglustat |
| US12472144B2 (en) * | 2017-08-08 | 2025-11-18 | Amneal Pharmaceuticals Llc | Pharmaceutical composition comprising eliglustat |
| BR112020011056A2 (pt) * | 2017-12-15 | 2020-11-17 | Genzyme Corporation | métodos para o tratamento da doença de gaucher |
| WO2019123476A1 (en) * | 2017-12-20 | 2019-06-27 | Sarudbhava Formulations Private Limited | Stable amorphous eliglustat premix and process for the preparation thereof |
| WO2019211778A2 (en) * | 2018-05-02 | 2019-11-07 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| AU2019276882A1 (en) * | 2018-05-27 | 2021-01-14 | Bioasis Technolgies Inc. | Treatment of gaucher disease |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| IL309862A (en) * | 2021-07-05 | 2024-02-01 | Ferrer Int | Medicines that include glycosidase inhibitors |
| CN116120274A (zh) * | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| WO1995005177A1 (en) | 1993-08-13 | 1995-02-23 | Seikagaku Corporation | Remedy for nervous diseases |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| EP0742789B1 (en) | 1994-02-02 | 2000-08-30 | The Liposome Company, Inc. | Pharmaceutically active compounds and liposomes, and methods of use therof |
| CN1152907A (zh) | 1994-06-10 | 1997-06-25 | 生化学工业株式会社 | 2-酰胺基丙醇化合物及其药物组合物 |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| JP2002521435A (ja) | 1998-07-27 | 2002-07-16 | ジョンズ・ホプキンス・ユニバーシティ | ラクトシルセラミドによって調節される病態を治療する方法 |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| EP1196406A1 (en) * | 1999-07-09 | 2002-04-17 | The Regents of the University of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US20040252299A9 (en) | 2000-01-07 | 2004-12-16 | Lemmo Anthony V. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| ATE338550T1 (de) | 2000-04-24 | 2006-09-15 | Teva Pharma | Mikronisierter zolpidem hemitartrat |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| BR0206400A (pt) | 2001-01-10 | 2005-01-18 | Univ Michigan | Compostos de amino ceramidas e seus usos em métodos terapêuticos |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| BR0116803A (pt) * | 2001-01-18 | 2004-02-17 | Merck Patent Gmbh | Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase |
| IL159905A0 (en) | 2001-07-16 | 2004-06-20 | Genzyme Corp | Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| AU2002328092A1 (en) | 2001-08-08 | 2003-02-24 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use as hiv inhibitors |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| WO2004004702A2 (en) | 2002-07-09 | 2004-01-15 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| AR047459A1 (es) * | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
| KR20070054246A (ko) | 2004-09-17 | 2007-05-28 | 유니버시티 오브 매사추세츠 | 리소좀성 효소 결핍을 위한 조성물 및 이의 용도 |
| EP1799865B1 (en) | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| ES2463681T3 (es) | 2004-10-13 | 2014-05-28 | Pharmacia & Upjohn Company Llc | Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6-oxopirimidin-1 (6H)-il]-N-(2-hidroxietil)-4-metilbenzamida |
| JP2008519840A (ja) * | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
| WO2007038676A2 (en) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of ladostigil tartrate |
| CA2624340A1 (en) * | 2005-10-03 | 2007-04-12 | Mallinckrodt Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| EP2032134B1 (en) * | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| US20080175908A1 (en) * | 2007-01-12 | 2008-07-24 | Wyeth | Tablet-in-tablet compositions |
| JP2010523578A (ja) | 2007-03-30 | 2010-07-15 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いるファブリー病の治療方法 |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| EP2594564B1 (en) * | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| US20090307181A1 (en) | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| KR20120107080A (ko) | 2009-11-27 | 2012-09-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| ES2693746T3 (es) | 2009-11-27 | 2018-12-13 | Adverio Pharma Gmbh | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo para su uso como principio activo farmacéutico |
| MY160542A (en) | 2009-11-27 | 2017-03-15 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| CN103619840B (zh) | 2011-06-21 | 2016-01-20 | 诺华股份有限公司 | (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物 |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Ceased
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 MX MX2017011301A patent/MX381242B/es unknown
- 2010-11-24 PH PH1/2015/502514A patent/PH12015502514B1/en unknown
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 KR KR1020247041119A patent/KR20250005503A/ko active Pending
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en not_active Ceased
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active Active
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active Ceased
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 PH PH1/2012/501048A patent/PH12012501048A1/en unknown
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en not_active Revoked
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active Ceased
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko not_active Ceased
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
-
2014
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en not_active Abandoned
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es not_active Application Discontinuation
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es not_active Application Discontinuation
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US12465586B2/en active Active
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512252A5 (enExample) | ||
| RU2670272C2 (ru) | Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений | |
| EP1985292A1 (en) | Titration of tapentadol | |
| AU2010289022B2 (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| US20090068290A1 (en) | Bifeprunox doses for treating schizophrenia | |
| TW200803857A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| JP2007533733A (ja) | 食物摂取管理の方法 | |
| WO2004054574A1 (ja) | 経口固形医薬 | |
| WO2014199294A1 (en) | Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| JPWO2002066030A1 (ja) | ジクロフェナクとオルノプロスチルからなる医薬組成物 | |
| JP7366108B2 (ja) | ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物 | |
| CN101316586A (zh) | 5-ht4激动剂用于治疗可以由质子泵抑制剂诱导的胃排空延迟的用途 | |
| JP2005097277A (ja) | 歯ぎしりの予防剤または治療剤 | |
| JP4355703B2 (ja) | 歯ぎしりの予防剤または治療剤 | |
| KR100709531B1 (ko) | 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물 | |
| WO2025038481A1 (en) | Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer | |
| WO2024042540A1 (en) | Mesdopetam compositions | |
| TWI589292B (zh) | 用於控管噁心及嘔吐之組合物 | |
| HK1207285B (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| WO2014203140A1 (en) | Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof | |
| JP2005314380A (ja) | インスリン抵抗性改善剤を含有する糖尿病治療剤 | |
| HK1080381A (en) | Drug composition for prevention or inhibition of advance of diabetic complication | |
| JP2010501604A (ja) | グルコースレベルを低下させる方法 |